Reaction

Device Physical Property Issue reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 7,386 reports · 73 co-occurring drugs

As of the last recalculation, Device Physical Property Issue appears in 7,386 FAERS reports alongside 73 co-occurring drug terms. The strongest observed disproportionality signal is SOMATROPIN (PRR 182.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Somatropin	2,902	182.7	190.2
Pegfilgrastim	1,387	48.5	49.2
Levonorgestrel	608	9.2	9.2
Ketoprofen	40	8.6	8.7
Epoprostenol	37	8.0	8.0
Carbidopa And Levodopa	99	5.9	6.0
Etonogestrel And Ethinyl Estradiol	46	5.9	5.9
Treprostinil	252	5.8	5.8
0Xygen	94	5.4	5.4
Oxygen	94	5.4	5.4
Amitriptyline Hydrochloride	33	5.3	5.3
Budesonide, Glycopyrrolate, And Formoterol Fumarate	17	4.6	4.6
Amantadine	23	4.2	4.2
Estradiol Gel 0.1%	61	3.8	3.8
Estradiol Transdermal	61	3.8	3.8
Rasagiline Mesylate	15	3.8	3.8
Estradiol	114	3.8	3.8
Sildenafil	73	3.6	3.6
Macitentan	87	3.6	3.6
Amikacin	19	3.1	3.1
Rotigotine	16	3.1	3.1
Lidocaine Hydrochloride	65	3.1	3.1
Pramipexole	16	2.9	2.9
Levodopa	12	2.8	2.8
Sodium Chloride Tablet	70	2.7	2.7
Sodium Chloride Tablets	70	2.7	2.7
Sodium Chloride	75	2.7	2.7
Dalteparin Sodium	10	2.7	2.7
Clonidine	47	2.6	2.6
Guanfacine	7	2.5	2.5
Cetirizine Hcl	8	2.5	2.5
Methylphenidate	24	2.3	2.3
Tadalafil	82	2.3	2.3
Tiotropium Bromide Inhalation Spray	9	2.3	2.3
Rivastigmine	15	2.2	2.2
Nemolizumab-Ilto	10	2.2	2.2
Torsemide	26	2.2	2.2
Guselkumab	27	2.1	2.1
Melatonin	41	2.1	2.1
Riociguat	24	2.1	2.1
Sildenafil Powder,	26	2.1	2.1
Ropinirole	11	2.0	2.0
Benralizumab	14	2.0	2.0
Anastrozole Tablets	15	2.0	2.0
Hydroxyzine Hydrochloride	9	1.9	1.9
Hydroxyzine Hydrochloride Oral	9	1.9	1.9
Sildenafil Citrate	85	1.9	1.9
Bumetanide	17	1.8	1.8
Filgrastim	23	1.7	1.7
Teduglutide	8	1.7	1.7
Paricalcitol	8	1.6	1.6
Ustekinumab	56	1.5	1.5
Memantine	7	1.4	1.4
Memantine Hydrochloride	7	1.4	1.4
Copper	21	1.4	1.4
Ofatumumab	16	1.4	1.4
Medroxyprogesterone Acetate	23	1.3	1.3
Romosozumab-Aqqg	6	1.2	1.2
Ambrisentan	55	1.2	1.2
Nintedanib	13	1.2	1.2
Abaloparatide	12	1.1	1.1
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	16	1.1	1.1
Erenumab-Aooe	20	1.0	1.0
Fremanezumab-Vfrm	4	1.0	1.0
Cannabidiol	8	1.0	1.0
Evolocumab	55	1.0	1.0
Umeclidinium Bromide And Vilanterol Trifenatate	5	0.8	0.8
Teriparatide	33	0.8	0.8
Ranolazine	3	0.8	0.8
Droxidopa	6	0.8	0.8
Etonogestrel	12	0.7	0.7
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	6	0.5	0.5
Pimavanserin Tartrate	9	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.